Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
- PMID: 16683009
- DOI: 10.1038/sj.pcan.4500879
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
Abstract
Most malignancies have increased glycolysis for energy requirement of rapid cell proliferation, which is the basis for tumor imaging through glucose analog FDG (2-deoxy-2-fluoro-D-glucose) with positron emission tomography. One of significant characteristics of prostate cancer is slow glycolysis and low FDG avidity. Recent studies showed that prostate cancer is associated with changes of fatty acid metabolism. Several enzymes involved in the metabolism of fatty acids have been determined to be altered in prostate cancer relative to normal prostate, which is indicative of an enhanced beta-oxidation pathway in prostate cancer. Increased fatty acid utilization in prostate cancer provides both ATP and acetyl-coenzyme A (CoA); subsequently, increased availability of acetyl-CoA makes acceleration of citrate oxidation possible, which is an important energy source as well. Dominant fatty acid metabolism rather than glycolysis has the potential to be the basis for imaging diagnosis and targeted treatment of prostate cancer.
Similar articles
-
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.Prostate. 2005 Jun 1;63(4):316-23. doi: 10.1002/pros.20177. Prostate. 2005. PMID: 15599942
-
Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.Cancer Res. 2009 Oct 15;69(20):8133-40. doi: 10.1158/0008-5472.CAN-09-0775. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826053
-
Fatty acid synthase: a metabolic oncogene in prostate cancer?J Cell Biochem. 2004 Jan 1;91(1):47-53. doi: 10.1002/jcb.10708. J Cell Biochem. 2004. PMID: 14689581 Review.
-
Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.Diabetes. 2007 Aug;56(8):2085-92. doi: 10.2337/db07-0093. Epub 2007 May 22. Diabetes. 2007. PMID: 17519422
-
Calcidiol and prostate cancer.J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):183-90. doi: 10.1016/j.jsbmb.2004.12.009. Epub 2005 Jan 22. J Steroid Biochem Mol Biol. 2005. PMID: 15860261 Review.
Cited by
-
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.Elife. 2020 Jul 20;9:e54166. doi: 10.7554/eLife.54166. Elife. 2020. PMID: 32686647 Free PMC article.
-
Sevoflurane but not propofol enhances ovarian cancer cell biology through regulating cellular metabolic and signaling mechanisms.Cell Biol Toxicol. 2023 Aug;39(4):1395-1411. doi: 10.1007/s10565-022-09766-6. Epub 2022 Oct 8. Cell Biol Toxicol. 2023. PMID: 36207479 Free PMC article.
-
Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology.J Proteome Res. 2013 Mar 1;12(3):1369-76. doi: 10.1021/pr301023x. Epub 2013 Jan 31. J Proteome Res. 2013. PMID: 23301521 Free PMC article.
-
The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.Cancer Metab. 2024 Aug 7;12(1):24. doi: 10.1186/s40170-024-00348-0. Cancer Metab. 2024. PMID: 39113152 Free PMC article.
-
Discovery of Lipid Metabolism-Related Genes for Predicting Tumor Immune Microenvironment Status and Prognosis in Prostate Cancer.J Oncol. 2022 Sep 5;2022:8227806. doi: 10.1155/2022/8227806. eCollection 2022. J Oncol. 2022. PMID: 36106334 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
